Original Article

You have full text access to this OnlineOpen article

Treatment of acute myelogenous leukemia with outpatient azacitidine

  1. Nimit Sudan MD,
  2. James M. Rossetti DO†,‡,*,
  3. Richard K. Shadduck MD†,
  4. Joan Latsko MSN, CRNP, OCN,
  5. John A. Lech DO,
  6. Robert B. Kaplan MD,
  7. Margaret Kennedy MD,
  8. Jeffrey F. Gryn MD,
  9. Yacoub Faroun MD,
  10. John Lister MD

Article first published online: 11 SEP 2006

DOI: 10.1002/cncr.22204

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1839–1843, 15 October 2006

Additional Information

How to Cite

Sudan, N., Rossetti, J. M., Shadduck, R. K., Latsko, J., Lech, J. A., Kaplan, R. B., Kennedy, M., Gryn, J. F., Faroun, Y. and Lister, J. (2006), Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer, 107: 1839–1843. doi: 10.1002/cncr.22204

Author Information

  1. Division of Hematology/Oncology, Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania

  1. †

    Drs. Rossetti and Shadduck are members of the Speakers Bureau of Pharmion Corp.

  2. ‡

    Fax: (412) 578-4391.

*Division of Hematology/Oncology, Western Pennsylvania Cancer Institute, Suite 2303N, 4800 Friendship Ave., Pittsburgh, PA, 15224

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 11 SEP 2006
  3. Manuscript Accepted: 13 JUL 2006
  4. Manuscript Revised: 21 JUN 2006
  5. Manuscript Received: 17 JAN 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (99K)

REFERENCES

  • 1
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 1051–1062.
  • 2
    Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268–1274.
  • 3
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997; 89: 3323–3329.
  • 4
    Creusot F, Acs G, Christman J. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-AZA-2'-deoxycytidine. J Biol Chem. 1982; 257: 2041–2048.
  • 5
    Christman J, Price P, Pedrinan L, Acs G. Correlation between hypomethylation of DNA and expression of globulin genes in Friend erythroleukemia cells. Eur J Biochem. 1977; 81: 53–61.
    Direct Link:
  • 6
    Saiki JH, McCredie KB, Vietti TJ, et al. 5-Azacytidine in acute leukemia. Cancer. 1978; 42: 2111–2114.
    Direct Link:
  • 7
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429–2440.
  • 8
    Gryn J, Zeigler ZR, Shadduck RK, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res. 2002; 26: 893–897.
  • 9
    JaffeES, HarrisNL, SteinH, VardimanJW (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
  • 10
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189–199.
  • 11
    Cheson BD, Bennett JM, Kantarjian H, et al. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671–3674.
  • 12
    Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8: 813–819.
  • 13
    Cheson BD, Bennett JM, Kopecky KJ, et al. and the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642–4649.
  • 14
    Lee EJ, Hogge DE, Gallagher R, Schiffer CA. Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia. 1990; 4: 835–838.
  • 15
    Silverman LR, McKenzie DR, Peterson BL, et al. Response rates in patients with acute myeloid leukemia treated with azacitidine, using WHO and IWG criteria for myelodysplastic syndrome. Blood. 2005; 106: 525a.
  • 16
    Van Slyck EJ, Rebuck JW, Waddell CC, Janakiraman N. Smoldering acute granulocytic leukemia. Observations on its natural history and morphologic characteristics. Arch Intern Med. 1983; 143: 37–40.
  • 17
    Baudard M, Legrand O, Marie JP, Zittoun R. Smoldering acute myelogenous leukemia in the elderly. Leuk Lymphoma. 1999; 34: 561–567.
View Full Article (HTML) Get PDF (99K)